The Case for Universal Varicella Zoster Virus Vaccination

By HEOR Staff Writer

January 11, 2024

Introduction:

The COVID-19 pandemic has monopolised the scientific community’s focus, often at the expense of other crucial health matters. One such overlooked area is the universal vaccination against the varicella zoster virus (VZV). This article explores the reasons behind the delay in its approval and the potential benefits it could bring to public health.

The Delay in Universal VZV Vaccination:

The Joint Committee on Vaccination and Immunisation (JCVI) in the UK, while proactive with COVID-19 immunisations, has been slow to approve the VZV vaccine. This delay has been largely due to the Hope-Simpson hypothesis, which posits that reducing VZV exposure could lead to an increase in herpes zoster (HZ) infections. However, real-world data from countries with a universal VZV immunisation program, such as the USA, contradict these fears.

Private Vaccinations and Epidemiological Concerns:

Despite the JCVI’s hesitance, many UK parents are opting for private VZV vaccinations for their children. The financial burden of children missing school due to chickenpox often outweighs the cost of the vaccine. However, these private vaccinations are not being counted by the UK Health Security Agency (UKHSA) or Department for Health and Social Care (DHSC), leading to an incomplete picture of the disease’s current burden.

The Potential Impact of Universal VZV Vaccination:

The JCVI has recently suggested that the multivalent Hib vaccine could be given at 18 months, freeing up space for the VZV vaccination. This change would require acceptance that the Hope-Simpson hypothesis does not carry significant weight. As a result, they have finally advised that the measles, mumps, and rubella (MMR) vaccines be given with the varicella vaccine at 12 and 18 months.

Remaining Concerns and the Way Forward:

While the risk of febrile seizures when combined with the MMR vaccine is low, some concerns remain. Governmental funding concerns around the cost of vaccination are valid. The indirect economic impact of lost days of work is far more significant. Universal VZV vaccination could also reduce vertical transmission and potentially protect immunosuppressed individuals.

Conclusion:

Our healthcare systems often fall prey to the inverse care law. However, by reducing time off from work for parents, universal VZV vaccination could have the greatest impact on those who earn the least, and potentially improve economic growth in the process.

Reference url

Recent Posts

Workshop on AI in GMP Manufacturing: Shaping Future Guidance from EMA

By HEOR Staff Writer

May 11, 2026

The European Medicines Agency is convening a two-day multistakeholder workshop to collect expert contributions that will inform the development of Annex 22 guidance on AI in GMP Manufacturing. Date: 30 June – 1 July 2026 Format: Hybrid The event features: ...
Developer Engagement Misalignment: Challenges in Assessing Advanced Therapies
Advanced Therapy Medicinal Products (ATMPs) offer transformative options for rare and previously untreatable conditions, yet their high upfront costs, uncertain durability, and single-arm trial data create major reimbursement barriers. The 2026 pre-proof study by Greco et al. shows that developer...
MEA Adoption Challenges in Advanced Therapy Medicinal Products: Insights and Implications
MEA Adoption Challenges continue to limit the practical use of Managed Entry Agreements for Advanced Therapy Medicinal Products across Europe. The 2026 pre-proof paper by Greco et al. draws on interviews with HTA bodies and payers in England, the Netherlands, and Spain to show that hybrid agreeme...